2.27  -0.04 (-1.73%)		07-15 16:00
Open: 2.34 High: 2.34 Volume: 292,530		Pre. Close: 2.31 Low: 2.23 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	3.18	1-year :	3.56
Resists	First :	2.72	Second :	3.04
Pivot price	2.53
Supports	First :	2.21	Second :	1.83
MAs	MA(5) :	2.34	MA(20) :	2.47
	MA(100) :	8.41	MA(250) :	102.27
MACD	MACD :	-0.5	Signal :	-0.6
%K %D	K(14,3) :	11.5	D(3) :	16.4
RSI	RSI(14): 33.1
52-week	High :	622.5	Low :	2.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CDT ] has closed above bottom band by 20.2%. Bollinger Bands are 87.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 102 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.46 - 2.48	2.48 - 2.49
Low:	2.26 - 2.27	2.27 - 2.29
Close:	2.29 - 2.31	2.31 - 2.33

Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Tue, 08 Jul 2025
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy - The Globe and Mail

Tue, 08 Jul 2025
First Nasdaq Pharma Company Explores Bitcoin Reserves While Advancing Drug Development - Stock Titan

Wed, 04 Jun 2025
Conduit Pharma Expands Drug Pipeline to $15B Animal Health Market Through Zero-Cost Development Deal - Stock Titan

Tue, 03 Jun 2025
Conduit Pharmaceuticals Sets 2025 Annual Meeting Date - TipRanks

Wed, 21 May 2025
Conduit Pharmaceuticals Inc. Regains Compliance with Nasdaq Listing Requirements - Nasdaq

Thu, 06 Mar 2025
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	18.3 (%)
Held by Institutions	3.6 (%)
Shares Short	103 (K)
Shares Short P.Month	51 (K)

EPS	-255.61
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.23
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-168.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0.53
Price to Sales	0
Price to Cash Flow	-0.47

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.